Cargando…
Thromboembolic events in COVID-19 ambulatory patients: An observational study about incidence, and thromboprophylaxis outcomes
INTRODUCTION: There are no clear data about the incidence and the prophylactic strategies of arterial and venous thromboembolic events (TE) in COVID-19 ambulatory patients. Thus, we conducted this study to analyze thromboembolic complications in this setting and to assess thromboprophylaxis manageme...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9352084/ https://www.ncbi.nlm.nih.gov/pubmed/35925930 http://dx.doi.org/10.1371/journal.pone.0270195 |
_version_ | 1784762575574007808 |
---|---|
author | Hammami, Rania Jdidi, Jihen Chakroun, Olfa Issaoui, Fadhila Ktata, Nouha Maamri, Hanen Baklouti, Mouna Bahloul, Amine Gargouri, Rania Nasri, Abdennour Msaad, Sameh Kammoun, Samy Kammoun, Samir Rejab, Imen Ben Charfeddine, Selma Abid, Leila |
author_facet | Hammami, Rania Jdidi, Jihen Chakroun, Olfa Issaoui, Fadhila Ktata, Nouha Maamri, Hanen Baklouti, Mouna Bahloul, Amine Gargouri, Rania Nasri, Abdennour Msaad, Sameh Kammoun, Samy Kammoun, Samir Rejab, Imen Ben Charfeddine, Selma Abid, Leila |
author_sort | Hammami, Rania |
collection | PubMed |
description | INTRODUCTION: There are no clear data about the incidence and the prophylactic strategies of arterial and venous thromboembolic events (TE) in COVID-19 ambulatory patients. Thus, we conducted this study to analyze thromboembolic complications in this setting and to assess thromboprophylaxis management and outcomes in the real life. PATIENTS AND METHODS: This is an observational study including Covid-19 ambulatory patients. We assessed incidence of venous and arterial TE events as well as thromboprophylaxis outcomes and hemorrhagic complications. We defined high risk thrombo-embolic factor according to the Belgian guidelines which are the only guidelines that described thromboprophylaxis in COVID-19 ambulatory patients. RESULTS: We included 2089 patients with a mean age of 43±16 years. The incidence of 30 days venous and arterial TE complications in our cohort was 1%. Venous thromboembolic complications occurred in 0.8% and arterial thromboembolic complications occurred in 0.3%.We noted at least one high-risk TE factor in 18.5% of patients but thromboprophylaxis was prescribed in 22.5% of the cases, LMWH in 18.1%, and Rivaroxaban in 3.7%. Hemorrhagic events occurred in eight patients (0.3%): five patients showed minor hemorrhagic events and three patients showed major ones (0.14%). CONCLUSIONS: Our study showed that the incidence of thromboembolic complications is very low in COVID-19 ambulatory patients. Paradoxically, there is an over prescription of thrombo-prophylaxis in this population. |
format | Online Article Text |
id | pubmed-9352084 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-93520842022-08-05 Thromboembolic events in COVID-19 ambulatory patients: An observational study about incidence, and thromboprophylaxis outcomes Hammami, Rania Jdidi, Jihen Chakroun, Olfa Issaoui, Fadhila Ktata, Nouha Maamri, Hanen Baklouti, Mouna Bahloul, Amine Gargouri, Rania Nasri, Abdennour Msaad, Sameh Kammoun, Samy Kammoun, Samir Rejab, Imen Ben Charfeddine, Selma Abid, Leila PLoS One Research Article INTRODUCTION: There are no clear data about the incidence and the prophylactic strategies of arterial and venous thromboembolic events (TE) in COVID-19 ambulatory patients. Thus, we conducted this study to analyze thromboembolic complications in this setting and to assess thromboprophylaxis management and outcomes in the real life. PATIENTS AND METHODS: This is an observational study including Covid-19 ambulatory patients. We assessed incidence of venous and arterial TE events as well as thromboprophylaxis outcomes and hemorrhagic complications. We defined high risk thrombo-embolic factor according to the Belgian guidelines which are the only guidelines that described thromboprophylaxis in COVID-19 ambulatory patients. RESULTS: We included 2089 patients with a mean age of 43±16 years. The incidence of 30 days venous and arterial TE complications in our cohort was 1%. Venous thromboembolic complications occurred in 0.8% and arterial thromboembolic complications occurred in 0.3%.We noted at least one high-risk TE factor in 18.5% of patients but thromboprophylaxis was prescribed in 22.5% of the cases, LMWH in 18.1%, and Rivaroxaban in 3.7%. Hemorrhagic events occurred in eight patients (0.3%): five patients showed minor hemorrhagic events and three patients showed major ones (0.14%). CONCLUSIONS: Our study showed that the incidence of thromboembolic complications is very low in COVID-19 ambulatory patients. Paradoxically, there is an over prescription of thrombo-prophylaxis in this population. Public Library of Science 2022-08-04 /pmc/articles/PMC9352084/ /pubmed/35925930 http://dx.doi.org/10.1371/journal.pone.0270195 Text en © 2022 Hammami et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Hammami, Rania Jdidi, Jihen Chakroun, Olfa Issaoui, Fadhila Ktata, Nouha Maamri, Hanen Baklouti, Mouna Bahloul, Amine Gargouri, Rania Nasri, Abdennour Msaad, Sameh Kammoun, Samy Kammoun, Samir Rejab, Imen Ben Charfeddine, Selma Abid, Leila Thromboembolic events in COVID-19 ambulatory patients: An observational study about incidence, and thromboprophylaxis outcomes |
title | Thromboembolic events in COVID-19 ambulatory patients: An observational study about incidence, and thromboprophylaxis outcomes |
title_full | Thromboembolic events in COVID-19 ambulatory patients: An observational study about incidence, and thromboprophylaxis outcomes |
title_fullStr | Thromboembolic events in COVID-19 ambulatory patients: An observational study about incidence, and thromboprophylaxis outcomes |
title_full_unstemmed | Thromboembolic events in COVID-19 ambulatory patients: An observational study about incidence, and thromboprophylaxis outcomes |
title_short | Thromboembolic events in COVID-19 ambulatory patients: An observational study about incidence, and thromboprophylaxis outcomes |
title_sort | thromboembolic events in covid-19 ambulatory patients: an observational study about incidence, and thromboprophylaxis outcomes |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9352084/ https://www.ncbi.nlm.nih.gov/pubmed/35925930 http://dx.doi.org/10.1371/journal.pone.0270195 |
work_keys_str_mv | AT hammamirania thromboemboliceventsincovid19ambulatorypatientsanobservationalstudyaboutincidenceandthromboprophylaxisoutcomes AT jdidijihen thromboemboliceventsincovid19ambulatorypatientsanobservationalstudyaboutincidenceandthromboprophylaxisoutcomes AT chakrounolfa thromboemboliceventsincovid19ambulatorypatientsanobservationalstudyaboutincidenceandthromboprophylaxisoutcomes AT issaouifadhila thromboemboliceventsincovid19ambulatorypatientsanobservationalstudyaboutincidenceandthromboprophylaxisoutcomes AT ktatanouha thromboemboliceventsincovid19ambulatorypatientsanobservationalstudyaboutincidenceandthromboprophylaxisoutcomes AT maamrihanen thromboemboliceventsincovid19ambulatorypatientsanobservationalstudyaboutincidenceandthromboprophylaxisoutcomes AT bakloutimouna thromboemboliceventsincovid19ambulatorypatientsanobservationalstudyaboutincidenceandthromboprophylaxisoutcomes AT bahloulamine thromboemboliceventsincovid19ambulatorypatientsanobservationalstudyaboutincidenceandthromboprophylaxisoutcomes AT gargourirania thromboemboliceventsincovid19ambulatorypatientsanobservationalstudyaboutincidenceandthromboprophylaxisoutcomes AT nasriabdennour thromboemboliceventsincovid19ambulatorypatientsanobservationalstudyaboutincidenceandthromboprophylaxisoutcomes AT msaadsameh thromboemboliceventsincovid19ambulatorypatientsanobservationalstudyaboutincidenceandthromboprophylaxisoutcomes AT kammounsamy thromboemboliceventsincovid19ambulatorypatientsanobservationalstudyaboutincidenceandthromboprophylaxisoutcomes AT kammounsamir thromboemboliceventsincovid19ambulatorypatientsanobservationalstudyaboutincidenceandthromboprophylaxisoutcomes AT rejabimenben thromboemboliceventsincovid19ambulatorypatientsanobservationalstudyaboutincidenceandthromboprophylaxisoutcomes AT charfeddineselma thromboemboliceventsincovid19ambulatorypatientsanobservationalstudyaboutincidenceandthromboprophylaxisoutcomes AT abidleila thromboemboliceventsincovid19ambulatorypatientsanobservationalstudyaboutincidenceandthromboprophylaxisoutcomes |